Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Sees Significant Growth in Short Interest

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 94,847 shares, an increase of 320.0% from the June 15th total of 22,583 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 483,454 shares, the days-to-cover ratio is currently 0.2 days.

Oncotelic Therapeutics Trading Up 5.9%

Shares of OTLC stock traded up $0.00 on Tuesday, reaching $0.04. 7,000 shares of the company’s stock were exchanged, compared to its average volume of 291,136. Oncotelic Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.11. The stock has a market capitalization of $16.44 million, a PE ratio of 0.06 and a beta of -0.27. The company’s fifty day simple moving average is $0.05 and its 200 day simple moving average is $0.05. The company has a current ratio of 0.11, a quick ratio of 0.11 and a debt-to-equity ratio of 0.01.

Oncotelic Therapeutics (OTCMKTS:OTLC) last posted its quarterly earnings results on Wednesday, April 15th. The company reported $0.59 EPS for the quarter.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.